Gliclazide
Overview
Authors
Affiliations
Gliclazide is a second-generation oral hypoglycemic drug used for the treatment of noninsulin-dependent diabetes mellitus. It belongs to the sulfonylurea class that stimulates insulin secretion from pancreatic β-cells by inhibiting ATP-dependent potassium channels. Gliclazide also possesses unique antioxidant properties and other beneficial hemobiological effects. This profile represents a comprehensive description of the physical properties, chemical synthesis, spectroscopic characterization (FTIR, H NMR, C NMR, UV, and single-crystal X-ray), methods of analysis, pharmacological actions, and pharmacokinetic and pharmacodynamic properties of the title drug.
Park H, Lee S, Kang P, Cho C, Jang C, Lee S Arch Pharm Res. 2025; .
PMID: 39760829 DOI: 10.1007/s12272-024-01528-8.
Mamale K, Shukla S, Mahale P, Mhaske A, Kaundal R, Shukla R Naunyn Schmiedebergs Arch Pharmacol. 2025; .
PMID: 39754682 DOI: 10.1007/s00210-024-03741-0.
Polydimethylsiloxane Organic-Inorganic Composite Drug Reservoir with Gliclazide.
Gedawy A, Al-Salami H, Dass C Int J Mol Sci. 2024; 25(7).
PMID: 38612802 PMC: 11012350. DOI: 10.3390/ijms25073991.
Dahlen A, Dashi G, Maslov I, Attwood M, Jonsson J, Trukhan V Front Pharmacol. 2022; 12:807548.
PMID: 35126141 PMC: 8807560. DOI: 10.3389/fphar.2021.807548.
Panda B, Krishnamoorthy R, Bhattamisra S, Shivashekaregowda N, Seng L, Patnaik S Sci Rep. 2019; 9(1):17331.
PMID: 31758056 PMC: 6874704. DOI: 10.1038/s41598-019-53996-4.